Sign in

CIK 0001785279

  • Emerging growth company

Metagenomi Therapeutics, Inc.

Sign in to watch
Ticker
MGX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
813909017
Phone
+1 510-871-4880
Business address
5959 HORTON STREET, 7TH FLOOR, EMERYVILLE, CA, 94608
Former names
Metagenomi, Inc., Metagenomi Technologies, LLC
  1. 4 Open-market sale Wein Matthew sold 930 shares at $1.87 ($1,744)
  2. 4 Open-market sale Chief Financial Officer sold 1,808 shares at $1.87 ($3,390)
  3. 4 Derivatives Options or other derivatives
  4. 3 Insider Initial Statement of Ownership
  5. 4 Open-market sale Chief Financial Officer sold 1,559 shares at $1.86 ($2,900)
  6. 4 Open-market sale Chief Financial Officer sold 6,265 shares at $2.88 ($18,043)
  7. 4 Grant or award Irish Jian acquired 70,471 shares (grant or award)
  8. 4 Derivatives Options or other derivatives
  9. 4 Grant or award Chief Scientific Officer acquired 69,316 shares (grant or award)
  10. 4 Grant or award Wein Matthew acquired 10,397 shares (grant or award)
  11. 4 Grant or award Chief Financial Officer acquired 69,316 shares (grant or award)
  12. 4 Grant or award Chief Medical Officer acquired 57,763 shares (grant or award)
  13. 4 Derivatives Options or other derivatives
  14. 4 Grant or award Harnest Simon acquired 11,552 shares (grant or award)
  15. 4 Grant or award Delaney Simren acquired 6,931 shares (grant or award)
  16. 4 Derivatives Options or other derivatives
  17. 4 Grant or award Chief Executive Officer acquired 118,992 shares (grant or award)
  18. 4 Open-market buy 10% owner bought 900,000 shares at an average $14.47 ($13,025,000)
  19. 4 Conversion 10% owner acquired 4,050,997 shares (conversion)
  20. 3 Insider Initial Statement of Ownership

Page 3 of 4 · 73 filings